The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation - PubMed (original) (raw)
. 1999 Apr 15;162(8):4472-81.
Affiliations
- PMID: 10201984
The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation
J A Gollob et al. J Immunol. 1999.
Abstract
IL-12 and IL-2 can stimulate mitogen- or CD3-activated T cells to proliferate, produce IFN-gamma, and kill tumor cells. The magnitude of these functional responses is greatly augmented when T cells are activated by the combination of IL-12 and IL-2. Although peripheral blood T cells are largely unresponsive to these cytokines without prior activation, a small subset of CD8+ T cells (CD8+CD18bright) is strongly activated by the combination of IL-12 and IL-2. In this report we show that the functional synergy between IL-12 and IL-2 in CD8+CD18bright T cells correlates with the activation of the stress kinases, p38 mitogen-activated protein (MAP) kinase and stress-activated protein kinase (SAPK)/Jun N-terminal kinase, but not with the activation of the extracellular signal-regulated kinases. The functional synergy between IL-2 and IL-12 is also associated with a prominent increase in STAT1 and STAT3 serine phosphorylation over that observed with IL-12 or IL-2 alone. By contrast, STAT tyrosine phosphorylation is not augmented over that seen with either cytokine alone. A specific inhibitor of p38 MAP kinase completely inhibits the serine phosphorylation of STAT1 and STAT3 induced by IL-12 and IL-2 and abrogates the functional synergy between IL-12 and IL-2 without affecting STAT tyrosine phosphorylation. This suggests that p38 MAP kinase may play an important role in regulating STAT serine phosphorylation in response to the combination of IL-12 and IL-2. Furthermore, these findings indicate that the optimal activation of T cells by IL-12 and IL-2 may depend on an interaction between the p38 MAP kinase and Janus kinase/STAT signaling pathways.
Similar articles
- Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components.
Schuringa JJ, Jonk LJ, Dokter WH, Vellenga E, Kruijer W. Schuringa JJ, et al. Biochem J. 2000 Apr 1;347 Pt 1(Pt 1):89-96. Biochem J. 2000. PMID: 10727406 Free PMC article. - IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21.
Kalina U, Kauschat D, Koyama N, Nuernberger H, Ballas K, Koschmieder S, Bug G, Hofmann WK, Hoelzer D, Ottmann OG. Kalina U, et al. J Immunol. 2000 Aug 1;165(3):1307-13. doi: 10.4049/jimmunol.165.3.1307. J Immunol. 2000. PMID: 10903731 - p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons.
Goh KC, Haque SJ, Williams BR. Goh KC, et al. EMBO J. 1999 Oct 15;18(20):5601-8. doi: 10.1093/emboj/18.20.5601. EMBO J. 1999. PMID: 10523304 Free PMC article. - The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses.
Rincón M, Flavell RA, Davis RA. Rincón M, et al. Free Radic Biol Med. 2000 May 1;28(9):1328-37. doi: 10.1016/s0891-5849(00)00219-7. Free Radic Biol Med. 2000. PMID: 10924852 Review. - Stress-activated kinases regulate protein stability.
Fuchs SY, Fried VA, Ronai Z. Fuchs SY, et al. Oncogene. 1998 Sep 17;17(11 Reviews):1483-90. doi: 10.1038/sj.onc.1202184. Oncogene. 1998. PMID: 9779995 Review.
Cited by
- Circulating free heme induces cytokine storm and pulmonary hypertension through the MKK3/p38 axis.
Valuparampil Varghese M, James J, Bharti D, Rischard F, Rafikova O, Rafikov R. Valuparampil Varghese M, et al. Am J Physiol Lung Cell Mol Physiol. 2024 Oct 1;327(4):L574-L586. doi: 10.1152/ajplung.00422.2022. Epub 2024 Aug 28. Am J Physiol Lung Cell Mol Physiol. 2024. PMID: 39197168 Free PMC article. - Chicken γδ T cells proliferate upon IL-2 and IL-12 treatment and show a restricted receptor repertoire in cell culture.
Linti AE, Göbel TW, Früh SP. Linti AE, et al. Front Immunol. 2024 Feb 13;15:1325024. doi: 10.3389/fimmu.2024.1325024. eCollection 2024. Front Immunol. 2024. PMID: 38420118 Free PMC article. - Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2.
Horton BL, D'Souza AD, Zagorulya M, McCreery CV, Abhiraman GC, Picton L, Sheen A, Agarwal Y, Momin N, Wittrup KD, White FM, Garcia KC, Spranger S. Horton BL, et al. JCI Insight. 2023 Oct 9;8(19):e172728. doi: 10.1172/jci.insight.172728. JCI Insight. 2023. PMID: 37669107 Free PMC article. - Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.
Azad T, Rezaei R, Singaravelu R, Pelin A, Boulton S, Petryk J, Onsu KA, Martin NT, Hoskin V, Ghahremani M, Marotel M, Marius R, He X, Crupi MJF, Hoang HD, Nik-Akhtar A, Ahmadi M, Zamani NK, Golshani A, Alain T, Greer P, Ardolino M, Dickinson BC, Tai LH, Ilkow CS, Bell JC. Azad T, et al. Nat Commun. 2023 May 26;14(1):3035. doi: 10.1038/s41467-023-38651-x. Nat Commun. 2023. PMID: 37236967 Free PMC article. - The JAK-STAT pathway at 30: Much learned, much more to do.
Philips RL, Wang Y, Cheon H, Kanno Y, Gadina M, Sartorelli V, Horvath CM, Darnell JE Jr, Stark GR, O'Shea JJ. Philips RL, et al. Cell. 2022 Oct 13;185(21):3857-3876. doi: 10.1016/j.cell.2022.09.023. Cell. 2022. PMID: 36240739 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous